Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vantictumab - Ashibio

Next Previous
Drug Profile

Vantictumab - Ashibio

Alternative Names: Anti-frizzled receptor monoclonal antibody - OncoMed; Anti-Fzd receptor monoclonal antibody - OncoMed; anti-Fzd7; Anti-Fzd7 receptor monoclonal antibody - OncoMed; OMP-18R5; Vantictumab

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Developer ashibio; OncoMed Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Frizzled receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Highest Development Phases

  • Clinical Phase Unknown Osteopetrosis
  • Discontinued HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 19 Aug 2025 Clinical trials in Osteopetrosis (unspecified route)
  • 19 Aug 2025 Discontinued - Phase-I for HER2-negative-breast-cancer (Late-stage disease, Combination therapy) in USA (IV) (Mereo BioPharma pipeline, August 2025)
  • 19 Aug 2025 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater, Late-stage disease) in USA (IV) (Mereo BioPharma pipeline, August 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top